Restoratives

About Novapeutics

Origin

Novapeutics LLC started as a biopharmaceutical company spun-out from the University of Pennsylvania situated at the Pennovation Works campus from the year 2013 to 2019 with three co-founding members.  We were developing a menin-MLL (Mixed Leukemia Lineage Protein) inhibitor (menin-MLL inhibitor), a small molecule (iMen ~500 Dalton) that inhibits the menin and MLL interaction as an oral therapeutic for type 2 diabetes (T2D).  This could be achieved by restoring the insulin producing beta cells would especially be useful for treating advanced stage T2D patients, many of whom suffer from inadequate and non-responsive beta cells in the pancreatic islet.

Regenerating beta cells could restore patients’ endogenous ability to produce normoglycemic factors, such as insulin and amylin to properly manage the blood sugar level.  Early stage T2D patients suffer from low insulin and/or may not respond effectively to insulin.